BioMarin Pharmaceutical Inc. saw its stock gain momentum after Jefferies raised its price target to $105, signaling strong confidence in the biotech firm. The company secured new revenue streams through a patent settlement with Ascendis Pharma, earning 20% royalties on U.S. sales and 18% on sales in the EU, Brazil, and South Korea until 2030. Additionally, BioMarin acquired Alesta Therapeutics for $275 million, adding a potential first oral therapy for Hypophosphatasia to its pipeline, strengthening its position in rare disease treatments and supporting future growth prospects.
Zoomd Technologies Ltd. reported a second-quarter EPS of $0.01, surpassing analyst estimates of $0.0038, signaling better-than-expected profitability. Although quarterly revenue was $7.67 million, slightly below the $8.41 million forecast, the compan...
Snowflake's stock surged following a price target increase to $405 by Cantor Fitzgerald analyst Thomas Blakey, signaling a 24.21% upside. Analysts expect strong Q2 results with earnings of $0.45 per share and revenues of $1.47 billion, reflecting nea...
Tesla has announced a significant increase in its 2026 capital budget to $25 billion, with a major portion allocated to expanding production of its Optimus robots. This move highlights Tesla's commitment to advancing robotics technology alongside its...
Burlington Stores' stock fell 7.6% after reporting Q2 earnings with adjusted EPS of $2.37 beating estimates, but revenue of $3.002 billion slightly missed expectations. The company showed 11% revenue growth and a 46.2% gross margin, marking its 15th ...
MidCap Financial Investment Corp (NASDAQ: MFIC) received a Buy rating upgrade from Compass Point, boosting its stock price by 1.35% to $9.75. As a Business Development Company, its dividends are a key attraction but are taxed as non-qualified income ...
